by admin | Feb 27, 2026 | press-releases-rss
This post was originally published on this site.PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026 CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with...
by admin | Feb 23, 2026 | press-releases-rss
This post was originally published on this site.IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating...
by admin | Jan 9, 2026 | press-releases-rss
This post was originally published on this site.– PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule – First randomized registrational trial to...
by admin | Jan 6, 2026 | press-releases-rss
This post was originally published on this site.IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing...
by admin | Dec 18, 2025 | press-releases-rss
This post was originally published on this site.Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCApplications for the fellowship are due on February 27, 2026...
by admin | Dec 5, 2025 | press-releases-rss
This post was originally published on this site.Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort P CORE-008 Cohort A Data in HR BCG-Naïve NMIBC demonstrates 88% CR and...